Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes
Academic Article
Publication Date:
2020
Short description:
Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes / Maffi, P., Lundgren, T., Tufveson, G., Rafael, E., Shaw, J.A.M., Liew, A., Saudek, F., Witkowski, P., Golab, K., Bertuzzi, F., Gustafsson, B., Daffonchio, L., Ruffini, P.A., Piemonti, L.. - In: DIABETES CARE. - ISSN 0149-5992. - 43:4(2020), pp. 710-718. [10.2337/dc19-1480]
abstract:
Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allo-transplant recipients.
Iris type:
1.1 Articolo in rivista
List of contributors:
Maffi, Paola; Lundgren, Torbjörn; Tufveson, Gunnar; Rafael, Ehab; Shaw, James A M; Liew, Aaron; Saudek, Frantisek; Witkowski, Piotr; Golab, Karolina; Bertuzzi, Federico; Gustafsson, Bengt; Daffonchio, Luisa; Ruffini, Pier Adelchi; Piemonti, Lorenzo
Published in: